Clinical Study
Ceruloplasmin and the Extent of Heart Failure in Ischemic and Nonischemic Cardiomyopathy Patients
Table 3
Baseline characteristics of patients with nonischemic cardiomyopathy.
| | Nonischemic cardiomyopathy (124) | NYHA II (21) | NYHA III (71) | NYHA IV (32) | value |
| Age (year) | | | | 0.110 | Male sex [ (%)] | 10 (47.6%) | 42 (59.2%) | 13 (40.6%) | 0.195 | Smoking [ (%)] | 5 (23.8%) | 24 (33.8%) | 6 (18.8%) | 0.258 | Alcohol [ (%)] | 4 (19.0%) | 15 (21.1%) | 3 (9.4%) | 0.347 | Hypertension [ (%)] | 12 (57.1%) | 34 (47.9%) | 19 (59.4%) | 0.498 | Diabetes mellitus [ (%)] | 4 (19.0%) | 7 (9.9%) | 7 (21.9%) | 0.225 | BMI (kg/m2) | 21.56 3.11 | | | 0.639 | ALT (U/L) | 17.33 12.50 | | | 0.052 | AST (U/L) | | | | 0.024* | Total cholesterol (mg/dL) | | | | 0.460 | LDL-C (mg/dL) | | | | 0.832 | Triglycerides (mg/dL) | | | | 0.537 | Creatinine (mg/dL) | | | | 0.292 | Uric acid (mg/dL) | | | | 0.044* | CK (IU/L) | | | | 0.451 | CK-MB (IU/L) | | | | 0.001* | Troponin I (ng/mL) | | | | 0.213 | CRP (mg/L) | | | | 0.002* | Homocysteic acid (μmol/L) | | | | 0.609 | LVEF (%) | | | | 0.022* | LVIDd (cm) | | | | 0.101 | LA (cm) | | | | 0.434 | Cardiac tonic [ (%)] | 6 (28.6%) | 40 (56.3%) | 22 (68.8%) | 0.017* | Diuretic [ (%)] | 7 (33.3%) | 64 (90.1%) | 30 (93.8%) | <0.001* | Nitrate [ (%)] | 9 (42.9%) | 49 (69.0%) | 25 (78.1%) | 0.024* | ACEI/ARB [ (%)] | 15 (71.4%) | 64 (90.1%) | 27 (84.4%) | 0.099 | Beta blockers [ (%)] | 12 (57.1%) | 53 (74.6%) | 18 (56.2%) | 0.107 | CCB [ (%)] | 7 (33.3%) | 12 (16.9%) | 10 (31.2%) | 0.140 | Aspirin/clopidogrel [ (%)] | 12 (57.1%) | 40 (56.3%) | 18 (56.2%) | 0.998 | Statins [ (%)] | 5 (23.8%) | 14 (19.7%) | 4 (12.5%) | 0.542 |
|
|
ACEI: angiotensin-converting enzyme inhibitor; ALT: alanine aminotransferase; ARB: angiotensin receptor blocker; AST: aspartate aminotransferase; BMI: body mass index; CCB: calcium channel blocker; CK: creatinine kinase; CK-MB: creatinine kinase-MB; CRP: C-reactive protein; HDL-C: high-density lipoprotein cholesterol; LA: left atrium; LDL-C: low-density lipoprotein cholesterol; LVEF: left-ventricular ejection fraction; LVIDd: left-ventricular internal diameter at end diastole.
*
among NYHA II, NYHA III, and NYHA IV subgroups.
|